Jason Aryeh, a director of Ligand Pharmaceuticals Incorporated, recently acquired 750 shares of the company. The buys took place at $87.01 per share, on September 03, 2019. Aryeh now owns 123,822 shares of the company. Aryeh operates out of San Diego, CA. Some additional info was provided as follows:
The purchase(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 15, 2019, in accordance with Rule 10b5-1.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $86.01 to $88.01, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the i
ssuer full information regarding the number of shares and prices at which the transaction was effected.
All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Ligand Pharmaceuticals Incorporated makes a similar move, sign up!
Other recent filings from the company include the following: